Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Glioma 2Glioblastoma 2Weight Loss 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Splenomegaly 1Sarcoma, Kaposi 1Oligodendroglioma 1Multiple Myeloma 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1HIV Infections 1Gliosarcoma 1Fever 1Fatigue 1Ependymoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia 1Acquired Immunodeficiency Syndrome 1

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × Ritonavir × Clear all
NCT05679388 2024-09-19

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

University of Chicago

Phase 1 Terminated
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT03066154 2024-06-03

DOP

The Netherlands Cancer Institute

Phase 1 Terminated
24 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡